US Patent

US12138233 — Methods of treating idiopathic hypersomnia

Method of Use · Assigned to Jazz Pharmaceuticals Ireland Ltd · Expires 2041-02-22 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating idiopathic hypersomnia using oxybate, specifically a mixture of oxybate salts.

USPTO Abstract

The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably a mixture of salts of oxybate (a mixed salt oxybate).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4044`	—

Patent Metadata

Patent number: US12138233
Jurisdiction: US
Classification: Method of Use
Expires: 2041-02-22
Drug substance claim: No
Drug product claim: No
Assignee: Jazz Pharmaceuticals Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.